drugset / Trial / NCT05095701

An Immunity Persistence Study of Live Attenuated Varicella Vaccine

NCT05095701

Phase 4 Enrolling by invitation 703 enrolled Sinovac (Dalian) Vaccine Technology Co., Ltd.
Non-randomizedParallel-groupOpen-labelPrevention

Summary

This an open phase Ⅳ clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunity persistence of live attenuated varicella vaccine at 5 and 8 years after primary immunization with live attenuated varicella vaccine.

Timeline

Start
2021-12-18
Primary completion
2021-12-19
Completion
2025-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Live Attenuated Varicella Vaccine Vaccine 0.5 ml

Indications